Outcome and risk factor of immune‐related adverse events and pneumonitis in patients with advanced or postoperative recurrent non‐small cell lung cancer treated with immune checkpoint inhibitors

BACKGROUND: Non‐small cell lung cancer (NSCLC) patients with pre‐existing respiratory diseases have been excluded in clinical trials of immune checkpoint inhibitor (ICI) therapy, and it is unknown whether the same degree of response can be expected as that in patients without pre‐existing respirator...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Thorac Cancer
Huvudupphovsmän: Isono, Taisuke, Kagiyama, Naho, Takano, Kenji, Hosoda, Chiaki, Nishida, Takashi, Kawate, Eriko, Kobayashi, Yoichi, Ishiguro, Takashi, Takaku, Youtaro, Kurashima, Kazuyoshi, Yanagisawa, Tsutomu, Takayanagi, Noboru
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons Australia, Ltd 2020
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7812074/
https://ncbi.nlm.nih.gov/pubmed/33201587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13736
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk